GlaxoSmithKline

The United States RNA Polymerase Inhibitor Market is projected to reach USD xx.x billion by 2031, driven by advancements in clinical diagnostics and precision medicine. Key players include Johnson & Johnson, AstraZeneca, and Pfizer. Market segments include types like Veliparib and applications in hospital, retail, and online pharmacies. Regional analysis highlights North America's dominance, Europe's strategic alliances, and Asia-Pacific's growing energy demand.

Pembrolizumab plus chemoradiotherapy significantly improved OS for women with high-risk locally advanced cervical cancer, making it the new standard of care.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

The article discusses the importance of SSR (Server-Side Rendering) in modern web development, emphasizing its role in enhancing performance and user experience. It highlights the use of SSR-service-entry.770d26512fc8d957974b.js as a key component in implementing SSR.

Bicara Therapeutics raised $315 million in IPO to fund a pivotal study for its head and neck cancer therapy, ficerafusp alfa, which targets EGFR and TGF-beta signaling. The drug, combined with Keytruda, showed a 54% overall response rate in advanced HNSCC patients, with 64% in HPV-negative cases. A Phase 2/3 trial is planned for 2025.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

European stock markets closed higher; Stoxx Europe 600 gained 0.72%, Swiss Market Index rose 0.46%, France's CAC increased 0.41%, FTSE up 0.39%, and Germany's DAX closed 0.92% higher. Eurostat reported a 0.3% decline in euro area industrial production and a 2.6% job vacancy rate in Q2. France's consumer price index rose 0.5% in August. HSBC discusses selling its South African unit, Grifols seeks consultancy for minority investors, GSK's Blenrep gets breakthrough therapy designation in China, and Ascendis Pharma reports clinical activity in ovarian cancer trial.

Moderna acknowledges slower-than-expected uptake of its RSV vaccine, mResvia, amid competition from GSK and Pfizer. The company adjusts its market expectations and financial guidance, cutting R&D spending and discontinuing several pipeline projects. Moderna plans to focus more on oncology and respiratory disease vaccines, aiming to launch five new products by 2027.

Moderna delays break-even goal to 2028, predicting 2025 sales below current year forecast, due to extended regulatory timelines for flu and cancer vaccines. Shares drop 17.1% to $65.88. Expects $2.5B-$3.5B in 2025 sales, below analyst forecast of $3.74B. Plans to submit FDA applications for RSV and COVID-influenza combo shots.

The article contains technical details about a PDF file structure, including metadata and viewer preferences.